Clinical trials: Anticoagulant Therapy
Nonvalvular Atrial Fibrillation
Prevention of Stroke and Systemic Embolic Events in Patients With Atrial Fibrillation
The main purpose of this study is to provide dose-guiding information by assessing the safety and tolerability of 4 different dosing regimens of an extended-release (ER) formulation of AZD0837 compared with well-controlled…
- Trial name
- NCT00684307
- Testing
- AZD0837, Vitamin-K antagonist at INR 2-3
- Volunteers
- 1,084 people
- Sponsor
- AstraZeneca
Venous Thromboembolism (VTE), Pulmonary Embolism
Hokusai Study in Pediatric Patients With Confirmed Venous Thromboembolism (VTE)
This is an event driven Phase 3, prospective, randomized, open-label, blinded endpoint evaluation (PROBE) parallel group study in subjects with confirmed VTE.
- Conditions
- Venous Thromboembolism (VTE), Pulmonary Embolism, Deep Vein Thrombosis (DVT)
- Trial name
- NCT02798471
- Testing
- Edoxaban, Standard of Care
- Where
- 140 sites in United States, Argentina and 32 more
- Volunteers
- 290 people
- Sponsor
- Daiichi Sankyo
Blood Coagulation Disorders, Acute Major Bleeding
Efficacy and Safety Study of BERIPLEX® P/N (Kcentra) Compared With Plasma in Patients With Acute Major Bleeding Caused by Anticoagulant Therapy
The purpose of this study is to evaluate efficacy, safety and tolerance of BERIPLEX® P/N (Kcentra) compared with plasma in regard to rapid reversal of coagulopathy induced by coumarin derivatives in subjects who require immediate…
- Trial name
- NCT00708435
- Testing
- Beriplex® P/N (Kcentra), Fresh frozen plasma
- Where
- 69 sites in United States, Belarus and 4 more
- Volunteers
- 216 people
- Sponsor
- CSL Behring
Atrial Fibrillation, Vascular Risk
Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE A)
The purpose of this study is to determine if the combination of clopidogrel 75mg once daily (od) plus aspirin 100mg daily (recommended dose) is better than aspirin alone (100mg daily recommended dose) for preventing vascular…
- Trial name
- NCT00249873
- Testing
- clopidogrel (SR25990C)
- Where
- 30 sites in United States, Argentina and 28 more
- Volunteers
- 7,554 people
- Sponsor
- Sanofi
Anticoagulants and Bleeding Disorders, Surgery
Residual Anti-Xa Activity After Last Treatment Dose of Enoxaparin
The main objective of this study is to determine the time interval following the last treatment dose of enoxaparin at which the amount of anti-Xa level activity is reliably less than 0.2 international unit per milliliter (IU/mL)…
- Conditions
- Anticoagulants and Bleeding Disorders, Surgery, Regional Anesthesia Morbidity
- Trial name
- NCT03296033
- Testing
- Enoxaparin
- Where
- United States
- Volunteers
- 122 people
- Sponsor
- Wake Forest University Health Sciences
Coronary Artery Disease
Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease
Recent studies indicate that anti-factor-Xa inhibition with low-dose rivaroxaban may have a role in the reduction of ischemic recurrences in patients with atherosclerotic disease manifestations.
- Trial name
- SWAP-AC (NCT04006288)
- Testing
- Clopidogrel, Prasugrel, ticagrelor
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- University of Florida
Liver Cirrhosis, Portal Vein Thrombosis
Efficacy and Safety of Anticoagulant Therapy in Portal Vein Thrombosis
The study is aimed at evaluating the efficacy and safety of anticoagulant therapy with nadroparin calcium and warfarin in patients with portal vein thrombosis (PVT).
- Trial name
- NCT04173429
- Testing
- Nadroparin calcium, warfarin
- Where
- China
- Volunteers
- 64 people
- Sponsor
- Qilu Hospital of Shandong University
Atrial Fibrillation, Stroke
Patient Convenience Study (RE-SONANCE)
The aim of this non-interventional study is to describe patient's perception of anticoagulant treatment when using Pradaxa to prevent stroke and systemic embolism while suffering from atrial fibrillation (according to its…
- Trial name
- NCT02684981
- Where
- 12 sites in Austria, Bulgaria and 10 more
- Volunteers
- 9,472 people
- Sponsor
- Boehringer Ingelheim
Cardiac Disease
Edoxaban for Prevention of Blood Vessels Being Blocked by Clots (Thrombotic Events) in Children at Risk Because of Cardiac Disease
A committee will judge the safety and effectiveness of edoxaban and the regular treatment (standard of care). All children in the study will receive free treatment.
- Trial name
- NCT03395639
- Testing
- Edoxaban, Standard of Care (SOC)
- Where
- 48 sites in United States, Austria and 12 more
- Volunteers
- 168 people
- Sponsor
- Daiichi Sankyo
Venous Thromboembolism
Tolerability , PK/PD and Safety of Dabigatran Etexilate Oral Liquid Formulation in Children < 1 Year of Age
The aim of the study is to investigate the safety and tolerability of dabigatran etexilate solution in children aged less than 1 year, to demonstrate comparable PK/PD relationship to older children and adults and to confirm…
- Trial name
- NCT02223260
- Testing
- dabigatran
- Where
- 4 sites in Canada, France and 1 more
- Volunteers
- 8 people
- Sponsor
- Boehringer Ingelheim
Atrial Fibrillation
Patient Convenience Study- NIS RELATE
The aim of this non-interventional study is to describe patient's perception of anticoagulant treatment when using Pradaxa® to prevent stroke and systemic embolism while suffering from atrial fibrillation (according to its…
- Trial name
- NCT02849509
- Testing
- Pradaxa (dabigatran), Vitamin K antagonist
- Where
- 50 sites in Indonesia, Malaysia and 3 more
- Volunteers
- 1,313 people
- Sponsor
- Boehringer Ingelheim
Atrial Fibrillation, Stroke
Intention to Prescribe/Take OAC Depending on the Number of Risk Diagrams , and Period for the Estimation of the Risk.
Randomized study concerning the effect of the number of risk diagrams (with treatment +/- without treatment), the period of stroke risk estimation (one year or five years) and the target of prescription (the patient with atrial…
- Trial name
- NCT02746107
- Testing
- decision aid
- Where
- Romania
- Volunteers
- 968 people
- Sponsor
- Cristian Baicus
Atrial Fibrillation (AF), Stroke
Safety and Tolerability of Abelacimab (MAA868) vs. Rivaroxaban in Patients With Atrial Fibrillation
The purpose of the ANT-006 study is to evaluate the bleeding profile of abelacimab relative to rivaroxaban in patients with atrial fibrillation (AF) at moderate-to-high risk of stroke.
- Trial name
- AZALEA-TIMI 71 (NCT04755283)
- Testing
- Abelacimab, Rivaroxaban
- Where
- 92 sites in United States, Canada and 5 more
- Volunteers
- 1,287 people
- Sponsor
- Anthos Therapeutics, Inc.
Thromboembolism
Phase III Study Testing Efficacy & Safety of Oral Dabigatran Etexilate vs Warfarin for 6 m Treatment for Acute Symp Venous Thromboembolism (VTE)
The general aim of this study is to determine the comparative safety and efficacy of dabigatran etexilate 150 mg bid administered orally and warfarin Pro re nata (As needed/PRN) to maintain an International Normalised Ratio (INR)…
- Trial name
- RE-COVER II (NCT00680186)
- Testing
- Warfarin, Dabigatran etexilate
- Where
- 220 sites in United States, Australia and 29 more
- Volunteers
- 2,589 people
- Sponsor
- Boehringer Ingelheim
Anticoagulant Therapy
In Vitro Diagnostic Test for DOAC in Urine
This trial is conducted to assess the performance and handling of the in vitro diagnostic (IVD) device for oral direct factor Xa and thrombin inhibitors from urine samples of patients on treatment with direct oral anticoagulants…
- Trial name
- PADOASU (NCT03182829)
- Testing
- DOAC Dipstick
- Where
- 18 sites in Germany
- Volunteers
- 880 people
- Sponsor
- Doasense GmbH
Atrial Fibrillation
Study of DU-176b Aged 80 Years or Older
The purpose of this study is to evaluate the efficacy and safety of edoxaban in patients with non-valvular NVAF aged 80 years or older who are ineligible for available oral anticoagulation therapy.
- Trial name
- NCT02801669
- Testing
- Du-176b
- Where
- 164 sites in Japan
- Volunteers
- 984 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Atrial Fibrillation
Adherence to New Oral Anticoagulation Therapy in Turkey
This study will compose a national database of drug adherence and investigate the factors that affect drug adherence in patients taking new oral anticoagulation therapy in Turkish Population.
- Trial name
- NOAC-TR (NCT02480920)
- Where
- Turkey (Türkiye)
- Volunteers
- 2,738 people
- Sponsor
- Cardiovascular Academy Society, Turkey
Arthroplasty, Replacement, Hip, Thrombosis
Study of the Efficacy and Safety of DU-176b in Preventing Blood Clots in Patients Undergoing Total Hip Replacement
Patients who undergo total hip replacement surgery are at greater risk of getting deep vein thrombosis (blood clots). This study evaluates the safety, tolerability and effectiveness of the study drug, DU-176b, in reducing the…
- Trial name
- NCT00107900
- Testing
- DU-176b
- Where
- United States
- Volunteers
- 606 people
- Sponsor
- Daiichi Sankyo
Atrial Fibrillation
A Study to Learn About the Effects of Medicines That Help in Thinning the Blood in People With Atrial Fibrillation (AF) Between 2016 and 2020 in France
The purpose of this study is to look at how many patients with AF had strokes, major bleeding and death in both people who had and had not taken any oral anticoagulant.
- Trial name
- SIFNOS (NCT05838664)
- Testing
- No OAC, VKA, apixaban
- Where
- France
- Volunteers
- 2,140,403 people
- Sponsor
- Pfizer
Upper Gastrointestinal Bleeding, Peptic Ulcer Hemorrhage
Anticoagulation With Enhanced Gastrointestinal Safety
This study is a pragmatic cluster randomized controlled trial to evaluate the effectiveness of a clinician-facing implementation strategy on the use of medication optimization (defined as either discontinuation of all…
- Conditions
- Upper Gastrointestinal Bleeding, Peptic Ulcer Hemorrhage, Anticoagulant-induced Bleeding
- Trial name
- AEGIS (NCT05563714)
- Testing
- Clinician Notification with Nurse Facilitation (CNNF), Wait list control
- Where
- United States
- Volunteers
- 341 people
- Sponsor
- University of Michigan